Central ND News

Senator John Hoeven has joined a friend-of-the-court brief led by Senator Cindy Hyde-Smith and U.S. Representative August Pfluger in a case before the U.S. Supreme Court that opposes the federal government’s deregulation of chemical abortion drugs. Hoeven expressed concern over the FDA's actions, stating, “The FDA is ignoring federal law by making these drugs readily available via mail across the country. This amicus brief outlines the importance of holding the FDA responsible for putting the safety of women and girls at risk. We remain committed to protecting the lives of the unborn and the wellbeing of mothers.”

Senator Hyde-Smith, chair of the Senate Pro-Life Caucus, emphasized the importance of holding the FDA accountable for endangering the lives of women and girls. She stated, “The intent of our friend-of-the-court brief makes the case for holding the FDA accountable for endangering the lives of women and girls in its march to make abortion-inducing drugs easily available. It is about taking to task a federal agency that has willingly and aggressively subverted federal law.”

The lawmakers' amicus brief outlines the significant health and safety risks posed by the FDA's deregulation of chemical abortion drugs. It argues that the FDA's actions have endangered patient health and safety by subverting patient safeguards in the FDCA and permitting mail-order distribution of these drugs in violation of federal law.

The brief was signed by a total of 26 Senators and 119 House members, including notable Senate cosigners such as Marco Rubio, James Risch, Ted Cruz, and Marsha Blackburn. The lawmakers are united in their effort to challenge the FDA's deregulation of chemical abortion drugs and to ensure the protection of women's health and safety in these matters.

The case, U.S. Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine, will be heard by the Supreme Court, and the lawmakers are hopeful that their amicus brief will be well received by the justices as they seek to address the FDA's actions regarding the availability of abortion-inducing drugs.